Levi & Korsinsky Investigates Possible Securities Fraud by Aquestive Therapeutics, Inc. (AQST)

Core Viewpoint - Aquestive Therapeutics, Inc. is under investigation for potential violations of federal securities laws following an FDA letter identifying deficiencies in its NDA application for Anaphylm, leading to a significant drop in stock price [1][2]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious medical conditions, including anaphylaxis [1]. - The company’s stock price fell by $2.18 (35.1%) to open at $4.03 in response to the FDA's findings [2]. Group 2: Regulatory Impact - The FDA's letter indicates that the deficiencies in the NDA application preclude any discussions regarding labeling and post-market commitments for Anaphylm [1]. - This regulatory setback could have significant implications for the company's market position and future revenue potential [1]. Group 3: Legal Implications - Levi & Korsinsky has initiated an investigation into the company, indicating potential legal ramifications for shareholders who may have suffered losses [2]. - The firm has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [3].